Earnings Feed
Start Free
Moderna, Inc.·4

Mar 3, 4:04 PM ET

Mock James M 4

4 · Moderna, Inc. · Filed Mar 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Moderna (MRNA) CFO James Mock Exercises Derivatives; Shares Withheld

What Happened James M. Mock, Chief Financial Officer of Moderna (MRNA), exercised/converted derivatives on February 27, 2026 (totaling 11,004 shares: 329 + 774 + 9,901). To satisfy tax withholding obligations, 5,323 of those shares (160 + 375 + 4,788) were withheld/paid at $51.71 per share, resulting in $275,252 in tax-withholding proceeds paid. On March 1, 2026, Mock was recorded as acquiring two RSU awards/awards totaling 87,208 shares (37,639 and 49,569), reported as derivative awards.

Key Details

  • Transaction dates: exercise/conversion and withholding on 2026-02-27; grants/awards recorded 2026-03-01. Form filed 2026-03-03 (within required reporting window).
  • Withheld/disposed shares for tax: 160 @ $51.71 ($8,274); 375 @ $51.71 ($19,391); 4,788 @ $51.71 ($247,587). Total tax withholding = $275,252.
  • Derivative conversions/exercises: 329, 774 and 9,901 shares reported as exercised/converted (some line items shown at $0.00 as a derivative conversion/formality).
  • Awards received: 37,639 and 49,569 RSU-type awards reported as acquired (derivative); vesting is subject to the company’s schedule (see footnotes).
  • Footnotes of note: F2 = shares withheld at the Reporting Person’s election to satisfy tax withholding; F3–F5/F7 describe 25% initial vest and subsequent quarterly vesting schedules; F6 notes future option vesting beginning March 1, 2027.
  • Shares owned after the transaction: not specified in the supplied summary of the filing.

Context

  • This appears to be a net share settlement/tax-withholding associated with exercises/conversions and RSU activity (not an open-market sale by the insider). Net-settlements to cover taxes are routine and do not necessarily indicate a view on the company’s prospects.
  • The filing was submitted on March 3, 2026 for transactions on Feb 27 and Mar 1, which is within the typical Form 4 reporting window (timely).

Insider Transaction Report

Form 4
Period: 2026-02-27
Moderna, Inc.MRNA
Mock James M
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-27+329→ 45,553 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-27$51.71/sh−160$8,274→ 45,393 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-27+774→ 46,167 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-27$51.71/sh−375$19,391→ 45,792 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-27+9,901→ 55,693 total
  • Tax Payment

    Common Stock

    [F2]
    2026-02-27$51.71/sh−4,788$247,587→ 50,905 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-02-27−329→ 1,315 total
    → Common Stock (329 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F4]
    2026-02-27−774→ 6,189 total
    → Common Stock (774 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F5]
    2026-02-27−9,901→ 29,705 total
    → Common Stock (9,901 underlying)
  • Award

    Stock Option (Right to Buy)

    [F6]
    2026-03-01+37,639→ 37,639 total
    Exercise: $53.57From: 2027-03-01Exp: 2036-03-01→ Common Stock (37,639 underlying)
  • Award

    Restricted Stock Units

    [F1][F7]
    2026-03-01+49,569→ 49,569 total
    → Common Stock (49,569 underlying)
Footnotes (7)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
  • [F3]25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
  • [F4]25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
  • [F5]25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
  • [F6]25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
  • [F7]25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Signature
/s/ James Dillon, As Attorney-in-Fact|2026-03-03

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT